1415314-22-5

Basic information

• Product Name: 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine
• Synonyms: 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine
• CAS NO: 1415314-22-5
• Molecular Formula: C₆H₃ClIN₃
• Molecular Weight: 279.46559
• Mol File: 1415314-22-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 2.34±0.1 g/cm3(Predicted)
• PKA: 0.35±0.30(Predicted)
• CAS DataBase Reference: 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine(1415314-22-5)
• EPA Substance Registry System: 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine(1415314-22-5)

Safety Data

• Hazardous Substances Data: 1415314-22-5(Hazardous Substances Data)

Usage

General Description

6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine is a chemical compound with the molecular formula C6H3ClIN3. It is a heterocyclic compound with a pyridine ring fused to a triazolopyridine ring, and chlorine and iodine substituents at specific positions on the ring structure. 6-Chloro-8-iodo-[1,2,4]triazolo[1,5-a]pyridine is commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical products. It has been studied for its potential biological activities and is known to exhibit antimicrobial and antiviral properties. Additionally, it has been used in the development of new drugs and as a molecular probe in biological research.

Upstream product

• 1415329-76-8 (Z)-N'-(5-chloro-3-iodopyridin-2-yl)-N-hydroxyformimidamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 211308-81-5 5-chloro-3-iodo-2-aminopyridine 
• 1415329-76-8 (Z)-N'-(5-chloro-3-iodopyridin-2-yl)-N-hydroxyformimidamide 
• 1072-98-6 5-chloro-2-pyridylamine 

Downstream Products

• 1415694-77-7 4-{8-[6-(2-Methyl-pyrrolidin-1-yl)-pyridin-2-ylamino]-[1,2,4]triazolo[1,5-a]pyridin-6-yl}-benzoic acid methyl ester 
• 1415694-80-2 4-{8-[6-(2-Methyl-pyrrolidin-1-yl)-pyridin-2-ylamino]-[1,2,4]triazolo[1,5-a]pyridin-6-yl}-benzoic acid 
• 1415695-23-6 Methyl 2-methoxy-4-(3-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzamido)benzoate 
• 1415695-07-6 tert-butyl 4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)piperidine-3-carboxamido)benzoate 
• 1415695-13-4 Methyl 3-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzoate 
• 1415695-14-5 potassium 4-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzoate 
• 1415694-69-7 4-(1-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)piperidine-3-carboxamido)benzoic acid hydrochloride 
• 1415694-78-8 2-methoxy-4-(3-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamido)benzoic acid hydrochloride 
• 1415694-88-0 (3-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)phenyl)methanol 2,2,2-trifluoroacetate 
• 1415694-90-4 (S)-N-(2-(dimethylamino)ethyl)-4-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide 2,2,2-trifluoroacetate 
• 1415694-92-6 (S)-(3-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl)methanol 2,2,2-trifluoroacetate 
• 1415694-95-9 (S)-3-(8-(6-(2-methylpyrrolidin-1-yl)pyridin-2-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide 2,2,2-trifluoroacetate 
• 1415694-82-4 4-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)-N-(2-(dimethylamino)ethyl)benzamide hydrochloride 
• 1415694-84-6 4-(8-(5,6-dimethoxypyridin-2-ylamino)-[1,2,4]-triazolo[1,5-a]pyridin-6-yl)benzamide 2,2,2-trifluoroacetate 

Relevant articles and documents

HETEROARYLS AND USES THEREOF

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Rational design of highly selective spleen tyrosine kinase inhibitors

A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.

TRIAZOLOPYRIDINE COMPOUNDS

The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.